Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
340 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-10-13)
Due Date
October 13, 2026
Grace Period Ends
April 13, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
24 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 13, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Jun 17, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 17, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 17, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 17, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 17, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| May 1, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Apr 24, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Oct 13, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 28, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 28, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 8, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 22, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 22, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 22, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 18, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 10, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 18, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 18, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 18, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 15, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 15, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 14, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 9, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, cancer, inflammatory diseases, and restenosis; vaccine preparations; vaccines; biological preparations in the nature of antibodies for use in the treatment of metabolic disorders, cancer, inflammatory diseases, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, cancer, inflammatory diseases, and restenosis; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for use in the treatment and prevention of metabolic disorders, cancer, inflammatory diseases, and restenosis; diagnostic preparations for medical or veterinary purposes; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorders, cancer, inflammatory diseases, and restenosis; sanitary preparations for medical use; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for use in the treatment of metabolic disorders, cancer, inflammatory diseases, and restenosis; none of the foregoing goods for use in connection with the treatment or prevention of ear disorders
Class 042
Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies
Additional Information
Design Mark
The mark consists of the term "MONJUVI" having a spherical shape appearing above the "i".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042